HBI Deals+Insights / Digital and AI

France’s obesity drug reimbursement plan could reshape insurers’ role in care

France will begin reimbursing anti-obesity medicines from mid-June 2026, becoming the first EU country to introduce public coverage for treatments including Wegovy and Mounjaro, produced by Danish pharma giant Novo Nordisk and American pharmaceutical company Eli Lilly respectively. The policy is intended to prioritise high-risk patients rather than general weight management. Access will be limited to patients with severe obesity, defined as a BMI of at least 40, or at least 35 where accompanied by conditions such as type 2 diabetes or cardiovascular disease.